Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Siren L.L.C.

Key Points

• Siren L.L.C. reduced its stake in Arrowhead Pharmaceuticals by **8.0%**, now holding approximately **2,669,880 shares** valued at **$34.01 million**.
• Analyst ratings for Arrowhead Pharmaceuticals show a mixed outlook, with Citigroup lowering its price target from **$21.00 to $17.00**, while Chardan Capital keeps a **buy** rating with a target of **$60.00**.
• Arrowhead Pharmaceuticals reported a quarterly earnings miss, with an EPS of **($1.26)** against a consensus estimate of **($0.94)**, alongside revenue of **$27.77 million** for the quarter.

Siren L.L.C. reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 8.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,669,880 shares of the biotechnology company's stock after selling 231,801 shares during the quarter. Arrowhead Pharmaceuticals accounts for approximately 2.0% of Siren L.L.C.'s portfolio, making the stock its 15th largest holding. Siren L.L.C. owned 1.93% of Arrowhead Pharmaceuticals worth $34,014,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC grew its position in Arrowhead Pharmaceuticals by 31.8% during the first quarter. Exchange Traded Concepts LLC now owns 49,247 shares of the biotechnology company's stock worth $627,000 after buying an additional 11,879 shares during the period. Raymond James Financial Inc. acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter worth about $651,000. GAMMA Investing LLC grew its position in Arrowhead Pharmaceuticals by 297.6% during the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock worth $28,000 after buying an additional 1,628 shares during the period. New York State Teachers Retirement System grew its position in Arrowhead Pharmaceuticals by 6.9% during the first quarter. New York State Teachers Retirement System now owns 148,376 shares of the biotechnology company's stock worth $1,890,000 after buying an additional 9,593 shares during the period. Finally, Principal Financial Group Inc. grew its position in Arrowhead Pharmaceuticals by 117.8% during the first quarter. Principal Financial Group Inc. now owns 629,075 shares of the biotechnology company's stock worth $8,014,000 after buying an additional 340,191 shares during the period. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Trading Down 1.4%

Shares of ARWR traded down $0.31 on Friday, hitting $22.03. 2,388,669 shares of the stock traded hands, compared to its average volume of 2,476,969. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $3.05 billion, a P/E ratio of -17.21 and a beta of 1.00. The stock's 50 day moving average is $17.71 and its two-hundred day moving average is $15.98. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $9.57 and a 1 year high of $27.34.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The company had revenue of $27.77 million for the quarter, compared to analyst estimates of $29.01 million. During the same quarter last year, the firm earned ($1.38) earnings per share. As a group, sell-side analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ARWR has been the topic of several recent research reports. Wall Street Zen downgraded shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, July 18th. Royal Bank Of Canada reduced their price target on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a report on Friday, August 8th. B. Riley raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 11th. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, August 11th. Finally, TD Cowen raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of "Buy" and a consensus price target of $43.14.

Insider Activity

In related news, insider James C. Hamilton sold 9,389 shares of the company's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $20.00, for a total transaction of $187,780.00. Following the transaction, the insider owned 262,122 shares of the company's stock, valued at approximately $5,242,440. This represents a 3.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 4.30% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.